|
Sven Kili
Chief Development Officer
CCRM
UK
|
Dr Sven Kili is the Chief Development Officer (CDO) for CCRM and OmniaBio
in Toronto. He is responsible for supporting all research, development, and
service provision of the various technology platforms within CCRM and
OmniaBio, drawing on his deep experience in creating and leading small and
large companies in the CGT space.
Sven maintains his role as Principal of Sven Kili Consulting Ltd. where he
provides specialist strategic consulting services to innovative Cell & Gene
Therapy companies with a focus on creation through to clinical development
and commercialisation, as well as investing.
He has deep experience in all stages of Cell & Gene Therapy development,
including previous roles as CEO of Antion Biosciences, where he built an
academic team into a financed, development company focussed on
engineered CAR-T therapies; he was also Head of Development for the CGT
division of GSK Rare Diseases where he led teams developing and
commercialising Gene Therapies for a variety of rare genetic disorders
including Strimvelis®, the first ex-vivo gene therapy to be approved for
children with ADA-SCID; Wiskott - Aldrich syndrome (WAS); Metachromatic
Leukodystrophy (MLD) and Beta-Thalassemia and others. Prior to this, he led
the Cell Therapy and Regenerative Medicine group for Sanofi (Genzyme)
Biosurgery which included the clinical development, approval, and
commercialisation activities of the first combined ATMP product in the EU for
MACI®. He and his team also prepared and submitted various Advanced
Therapy regulatory filings for Australia and the US, including health
technology assessments and he was responsible for late stage developments
for Carticel® and Epicel® in the US. Before joining Genzyme, Sven led the cell
therapy activities and oversaw all UK & Irish regulatory functions and was the
EU QPPV for pharmacovigilance for the Geistlich Pharma. Sven trained as an
Orthopaedic surgeon in the UK and South Africa and since leaving full-time
clinical practise has developed expertise Cell and Gene Therapy strategic
company formation, clinical development, regulatory compliance, value
creation, risk management and product safety, product launches and postmarketing
activities.
He chairs a number of boards, including UK BIA CGTAC, UK Innovation Hubs,
ARM Gene Therapy committee, CCRM Investment Committee and co-chairs
ISCT Business Development and Finance committee. He further sits on the
LGC Corporation SAB, ISCT Strategic Advisory Council and Saisei Ventures
Investment Board.
Sven received an academic appointment as Chair at UCL for the course “MSc
in Manufacture and Commercialisation of Stem Cell and Gene Therapies”
where he leads the course steering committee. He still maintains his surgical
& clinical skills in the UK NHS and serves as an ATLS Instructor and SCUBA
diving instructor trainer in his spare time.
in Toronto. He is responsible for supporting all research, development, and
service provision of the various technology platforms within CCRM and
OmniaBio, drawing on his deep experience in creating and leading small and
large companies in the CGT space.
Sven maintains his role as Principal of Sven Kili Consulting Ltd. where he
provides specialist strategic consulting services to innovative Cell & Gene
Therapy companies with a focus on creation through to clinical development
and commercialisation, as well as investing.
He has deep experience in all stages of Cell & Gene Therapy development,
including previous roles as CEO of Antion Biosciences, where he built an
academic team into a financed, development company focussed on
engineered CAR-T therapies; he was also Head of Development for the CGT
division of GSK Rare Diseases where he led teams developing and
commercialising Gene Therapies for a variety of rare genetic disorders
including Strimvelis®, the first ex-vivo gene therapy to be approved for
children with ADA-SCID; Wiskott - Aldrich syndrome (WAS); Metachromatic
Leukodystrophy (MLD) and Beta-Thalassemia and others. Prior to this, he led
the Cell Therapy and Regenerative Medicine group for Sanofi (Genzyme)
Biosurgery which included the clinical development, approval, and
commercialisation activities of the first combined ATMP product in the EU for
MACI®. He and his team also prepared and submitted various Advanced
Therapy regulatory filings for Australia and the US, including health
technology assessments and he was responsible for late stage developments
for Carticel® and Epicel® in the US. Before joining Genzyme, Sven led the cell
therapy activities and oversaw all UK & Irish regulatory functions and was the
EU QPPV for pharmacovigilance for the Geistlich Pharma. Sven trained as an
Orthopaedic surgeon in the UK and South Africa and since leaving full-time
clinical practise has developed expertise Cell and Gene Therapy strategic
company formation, clinical development, regulatory compliance, value
creation, risk management and product safety, product launches and postmarketing
activities.
He chairs a number of boards, including UK BIA CGTAC, UK Innovation Hubs,
ARM Gene Therapy committee, CCRM Investment Committee and co-chairs
ISCT Business Development and Finance committee. He further sits on the
LGC Corporation SAB, ISCT Strategic Advisory Council and Saisei Ventures
Investment Board.
Sven received an academic appointment as Chair at UCL for the course “MSc
in Manufacture and Commercialisation of Stem Cell and Gene Therapies”
where he leads the course steering committee. He still maintains his surgical
& clinical skills in the UK NHS and serves as an ATLS Instructor and SCUBA
diving instructor trainer in his spare time.